Population
Patients with coronary artery disease, specifically acute coronary syndrome, undergoing percutaneous…
Design
Review
Key result
Individualization of dual antiplatelet therapy duration based on comprehensive assessment of ischemic and bleeding risks is recommended for patients with coronary artery disease.
Authors
Loading...
Supports risk-based DAPT individualization in CAD; leaves open validated tools for routine ischemic-bleeding balance.
This review summarizes the evidence for individualizing the duration of dual antiplatelet therapy and triple therapy in patients undergoing percutaneous coronary intervention based on ischemic and bleeding risks.
Chaturvedula et al. (2018) conducted a review in Coronary Artery Disease. Dual Antiplatelet Therapy (DAPT) was evaluated. Individualization of dual antiplatelet therapy duration based on comprehensive assessment of ischemic and bleeding risks is recommended for patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: